NASDAQ:QTRX
Quanterix Corporation Stock News
$12.72
+0.0400 (+0.315%)
At Close: Jul 02, 2024
Quanterix to Participate at the Scotiabank Healthcare 1x1 Day
04:00pm, Monday, 17'th Jun 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer
Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
04:00pm, Wednesday, 05'th Jun 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
04:00pm, Wednesday, 22'nd May 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer
Wall Street Analysts Believe Quanterix (QTRX) Could Rally 67.66%: Here's is How to Trade
10:56am, Wednesday, 15'th May 2024
The consensus price target hints at a 67.7% upside potential for Quanterix (QTRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
Quanterix Corporation (QTRX) Q1 2024 Earnings Call Transcript
02:40pm, Wednesday, 08'th May 2024
Quanterix Corporation (NASDAQ:QTRX ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Francis Pruell - Investor Relations Masoud Toloue - President and Chief Executive Offi
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
06:11pm, Tuesday, 07'th May 2024
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.16 per share a year ago.
Quanterix To Report First Quarter 2024 Financial Results
04:00pm, Monday, 29'th Apr 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure
05:30pm, Thursday, 21'st Mar 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
10:51am, Wednesday, 06'th Mar 2024
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease
09:00am, Monday, 04'th Mar 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phosp
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Thursday, 29'th Feb 2024
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.50 per share a year ago.
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
04:00pm, Thursday, 29'th Feb 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fo
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
11:06am, Tuesday, 27'th Feb 2024
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
06:58pm, Monday, 26'th Feb 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31,
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaboratio
